MPLT

The stock remains in a Stage 2 advancing regime with intact long- and medium-term uptrends, but extreme overbought conditions and recent parabolic extension signal that entry timing is poor; waiting for a pullback into rising 9/21 EMA support before engaging offers a better risk profile.

• ↑Phase 2 IRIS trial showed significant irritability reduction, enabling FDA discussions.
• ↑13F filings show >1.15 institutional ownership, reflecting robust investor support.
• ↓Q1 2026 net loss widened to -$1.34 per share, exceeding forecasts.